C-7 configuration as one of determinants in taxanes metabolism by human cytochrome P450 enzymes

Xenobiotica

Volumn 39, Issue 12, 2009, Pages 903-914

  Zhang, Y Y ^a,c   Liu, Y ^a   Zhang, J W ^a   Ge, G B ^a   Liu, H X ^a,c   Wang, L M ^b   Sun, J ^b   Yang, L ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

7 epi 10 deacetyl paclitaxel; 7 Epi cephalomannine; Cytochrome P450; Metabolism; Paclitaxel; Structure metabolism relationships

Indexed keywords

10 DEACETYL PACLITAXEL; 7 EPI CEPHALOMANNINE; 7 EPI DEACETYL PACLITAXEL; CEPHALOMANNINE; CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DITERPENOID; DOCETAXEL; PACLITAXEL; PACLITAXEL DERIVATIVE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG BINDING; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME METABOLISM; EPIMERIZATION; HUMAN; HUMAN CELL; HYDROXYLATION; INCUBATION TIME; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MONOHYDROXYLATION; PHARMACOLOGICAL PARAMETERS;

BRIDGED COMPOUNDS; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYLATION; ISOENZYMES; KINETICS; MALE; MICROSOMES, LIVER; MOLECULAR CONFORMATION; PACLITAXEL; RECOMBINANT PROTEINS; TAXOIDS;

EID: 70849122482     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498250903271989     Document Type: Article

References (36)

1. Baker AF, Dorr RT. (2001). Drug interactions with the taxanes: clinical implications. Cancer Treat Rev 27(4):221-233
2. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43(5):443-469
3. Colombo T, Frapolli R, Bombardelli E, Morazzoni P, Riva A, D'Incalci M, Zucchetti M. (1999). High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma. J Chromatogr B Biomed Sci Appl 736(1-2):135-141
4. Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, Gueritte F. (2002). Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos 30(4):438-445
5. Emoto C, Murase S, Sawada Y, Jones BC, Iwasaki K. (2003). In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalysed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. Drug Metab Pharmacokinet 18(5):287-295
6. Frapolli R, Marangon E, Zaffaroni M, Colombo T, Falcioni C, Bagnati R, Simone M, D'Incalci M, Manzotti C, Fontana G, Morazzoni P, Zucchetti M. (2006). Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i- butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors. Drug Metab Dispos 34(12):2028-2035
7. Gao Q, Parker WL. (1996). The 'hydrophobic collapse' conformation of paclitaxel (Taxol?) has been observed in a non-aqueous environment: Crystal structure of 10-deacetyl-7-epitaxol. Tetrahedron 52(7):2291-2300
8. Ge GB, Luan HW, Zhang YY, He YQ, Liu XB, Li Y, Wang ZT, Yang L. (2008). Profiling of yew hair roots from various species using ultra-performance liquid chromatography/electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom 22(15):2315-2323
9. Ge GB, Zhang R, Ai CZ, He YQ, Zhang YY, Liu XB, Yang L, Wang ZT, Yang L. (2009). Stereochemical differentiation of C-7 hydroxyltaxane isomers by electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom 23(3):425-432
10. Gligorov J, Lotz JP. (2004). Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9 Suppl. 2:3-8
11. Gut I, Ojima I, Vaclavikova R, Simek P, Horsky S, Linhart I, Soucek P, Kondrova E, Kuznetsova LV, Chen J. (2006). Metabolism of new-generation taxanes in human, pig, minipig and rat liver microsomes. Xenobiotica 36(9):772-792
12. Kingston DG. (2007). The shape of things to come: structural and synthetic studies of taxol and related compounds. Phytochemistry 68:1844-1854
13. Kumar D, Tomar RS, Deolia SK, Mitra M, Mukherjee R, Burman AC. (2007). Isolation and characterization of degradation impurities in docetaxel drug substance and its formulation. J Pharm Biomed Anal 43(4):1228-1235
14. Li J, Liu Y, Zhang JW, Wei H, Yang L. (2006). Characterization of hepatic drug-metabolizing activities of Bama miniature pigs (Sus scrofa domestica): comparison with human enzyme analogs. Comparat Med 6:286-290
15. Li XQ, Björkman A, Andersson TB, Ridderström M, Masimirembwa CM. (2002). Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 300(2):399-407
16. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
17. Melet A, Marques-Soares C, Schoch GA, Macherey AC, Jaouen M, Dansette PM, Sari MA, Johnson EF, Mansuy D. (2004). Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry 43(49):15379-15392
18. Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D, Mross K. (2005). Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11(13):4843-4850 (Pubitemid 41557204)
19. Monsarrat B, Thoison O, Dubois J, Cresteil T. (2009). Molecular determinant of regioselective hydroxylation of docetaxel by CYP3A4. Mol Cell Pharmacol 1(2):76-84
20. Nicoletti MI, Colombo T, Rossi C, Monardo C, Stura S, Zucchetti M, Riva A, Morazzoni P, Donati MB, Bombardelli E, D'Incalci M, Giavazzi R. (2000). IDN5109, a taxane with oral bioavailability and potent antitumor activity. Cancer Res 60(4):842-846
21. Omura T, Sato R. (1964). The carbon monoxide-binding pigment of liver microsomes. I. evidence for its hemoprotein nature. J Biol Chem 239:2370-2385
22. Rae JM, Soukhova NV, Flockhart DA, Desta Z. (2002). Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Disposit 30(5):525-530
23. Royer I, Alvinerie P, Armand JP, Ho LK, Wright M, Monsarrat B. (1995). Paclitaxel metabolites in human plasma and urine: identification of 6?-hydroxytaxol, 7-epitaxol and taxol hydrolysis products using liquid chromatography/atmospheric-pressure chemical ionization mass spectrometry. Rapid Comm Mass Spectrom 9:495-502
24. Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF. (2004). Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem 279(10):9497-9503
25. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV. (1998). Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8(5):391-401
26. Somlo G, Doroshow JH, Synold T, Longmate J, Reardon D, Chow W, Forman SJ, Leong LA, Margolin KA, Morgan RJ Jr, Raschko JW, Shibata SI, Tetef ML, Yen Y, Kogut N, Schriber J, Alvarnas J. (2001). High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome. Br J Cancer 84(12):1591-1598
27. Sugahara S, Kajiki M, Kuriyama H, Kobayashi TR. (2007). Complete regression of xenografted human carcinomas by a paclitaxelcarboxymethyl dextran conjugate (AZ10992). J Contr Release 117(1):40-50
28. Tian J, Stella VJ. (2008). Degradation of paclitaxel and related compounds in aqueous solutions I: epimerization. J Pharm Sci 97(3):1224-1235
29. Vaclavikova R, Horsky S, Simek P, Gut I. (2003). Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn Schmiedeberg's Arch Pharmacol 368(3):200-209
30. Vaclavikova R, Soucek P, Svobodova L, Anzenbacher P, Simek P, Guengerich FP, Gut I. (2004). Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs. Drug Metab Disposit 32(6):666-674
31. Walsky RL, Obach RS. (2004). Validated assays for human cytochrome P450 activities. Drug Metab Disposit 32(6):647-660
32. Zhang D, Ly VT, Lago M, Tian Y, Gan J, Humphreys WG, Cömezoglu SN. (2009a). CYP3A4-mediated ester cleavage as the major metabolic pathway of the oral taxane3?-tert-butyl-3?-N tert-butyloxycarbonyl-4-deacetyl-3?-dephenyl-3?-N- debenzoyl-4-O-methoxycarbonyl-paclitaxel (BMS-275183). Drug Metab Dispos 37(4):710-718
33. Zhang JW, Ge GB, Liu Y, Wang LM, Liu XB, Zhang YY, Li W, He YQ, Wang ZT, Sun J, Xiao HB, Yang L. (2008a). Taxane's substituents at C3 affect its regioselective metabolism: different in vitro metabolism of cephalomannine and paclitaxel. Drug Metab Dispos 36(2):418-426
34. Zhang JW, Liu Y, Cheng J, Li W, Ma H, Liu HT, Sun J, Wang LM, He YQ, Wang Y, Wang ZT, Yang L. (2007). Inhibition of human liver cytochrome P450 by star fruit juice. J Pharm Pharmaceut Sci 10(4):496-503
35. Zhang JW, Liu Y, Zhao JY, Wang LM, Ge GB, Gao Y, Li W, Liu HT, Liu HX, Zhang YY, Sun J, Yang L. (2008b). Metabolic profiling and cytochrome P450 reaction phenotyping of medroxyprogesterone acetate. Drug Metab Dispos 36(11):2292-2298
36. Zhang YY, Liu Y, Zhang JW, Ge GB, Wang LM, Sun J, Yang L. (2009b). Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel. Xenobiotica 39(4):283-292